Saros Therapeutics develops a proprietary nanoparticle platform that targets innate immune cells to enhance immune responses in patients with cancer and autoimmune diseases. This technology addresses the limitations of untargeted therapies by providing a safer and more effective approach to immunotherapy.
Funding
$2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NCFounders
Product
Problem
Current cancer and autoimmune disease immunotherapies often lack precise targeting, leading to off-target effects and suboptimal immune activation. This can result in limited efficacy and significant toxicity, hindering the potential for curative responses.
Solution
Saros Therapeutics is developing a targeted immunotherapy platform based on proprietary nanoparticles designed to selectively activate innate immune cells. These nanoparticles deliver immune-modulating payloads directly to specific immune cell populations, enhancing the desired immune response while minimizing systemic side effects. By re-engineering innate immune activation, Saros aims to generate safe, robust, and durable responses in patients with cancer and autoimmune disorders, overcoming the limitations of untargeted approaches. This targeted approach allows for a more precise and effective modulation of the immune system, potentially leading to improved clinical outcomes.
Target Audience
The primary target audience includes patients with cancer and autoimmune diseases who are seeking more effective and less toxic immunotherapy options, as well as pharmaceutical companies looking to develop next-generation immunotherapies.
Features
- Proprietary nanoparticle platform for targeted delivery to innate immune cells
- Selective activation of key immune pathways for enhanced efficacy
- Minimized off-target effects and reduced systemic toxicity
- Customizable nanoparticle design for diverse therapeutic payloads
- Potential for durable and curative responses in cancer and autoimmune diseases